QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

RIGL

QT83Rigel Pharmaceuticals, Inc.
NASDAQ·Healthcare·Biotechnology·USA
Latest market price
32.91
-0.46-1.38%
OverviewShort InterestFilings
RIGLQT83Rigel Pharmaceuticals, Inc.·NASDAQ
OverviewShort InterestFilings
32.91-1.38%
TA
Loading chart...
Screen all →
VRTX-1.60%$451.63REGN+0.33%$609.94ARGX-1.63%$877.72ALNY-1.64%$278.09RVMD+3.31%$162.99MRNA+3.50%$63.96UTHR-2.70%$536.59BNTX-1.44%$90.89
Snapshot
Index-P/E1.69EPS (ttm)
18.72
Insider Own-
Shs Outstand18.50M
Perf Week2.59%
Market Cap617.41MForward P/E7.52EPS next Y4.38Insider Trans0.76%Shs Float-Perf Month16.29%
Enterprise Value638.72MPEG0.00EPS next Q0.21Inst Own-Short Float-Perf Quarter26.09%
Income366.00MP/S2.06EPS this Y-83.18%Inst Trans-Short Ratio-Perf Half Y-21.68%
Sales299.77MP/B1.54EPS next Y38.98%ROA72.18%Short Interest-Perf YTD-23.16%
Book/sh21.62P/C7.75EPS next 5Y4.37%ROE147.03%52W High52.24 -37.00%Perf Year71.76%
Cash/sh7.95P/FCF7.79EPS past 3/5Y-ROIC27.96%52W Low18.14 81.42%Perf 3Y-
Dividend Est.-EV/EBITDA4.87Sales past 3/5Y34.81% 21.95%Gross Margin93.39%Volatility3.34% 3.10%Perf 5Y-
Dividend TTM-EV/Sales2.13EPS Y/Y TTM538.38%Oper. Margin41.56%ATR (14)1.50Perf 10Y-
Dividend Ex-Date-Quick Ratio2.48Sales Y/Y TTM67.60%Profit Margin121.50%RSI (14)62.57Recom2.47
Dividend Gr. 3/5Y-Current Ratio2.62EPS Q/Q-30.16%SMA206.76%Beta0.92Target Price27.33
Payout0.00%Debt/Eq0.11Sales Q/Q11.32%SMA509.00%Rel Volume2.46Prev Close33.37
Employees162LT Debt/Eq0.06EarningsAug 04SMA200-3.38%Avg Volume395.43KPrice32.91
IPO DateNov 29, 2000Option/ShortYes / YesEPS/Sales Surpr.-40.54% -4.84%Net Debt/EBITDA0.16Volume972,697Change-1.38%
Analyst Ratings
DateActionAnalystRatingTarget
Nov-05-25ReiteratedCantor FitzgeraldNeutral$38
Nov-05-25UpgradeJefferiesHold → Buy$1.00 → $42
Dec-02-22UpgradeCitigroupNeutral → Buy
Aug-17-22ReiteratedPiper SandlerNeutral$2.00
Jun-09-22DowngradeCitigroupBuy → Neutral
Jun-08-22ReiteratedJefferiesBuy$1.00
Jun-08-22DowngradeCantor FitzgeraldOverweight → Neutral
Nov-09-20DowngradeJP MorganOverweight → Neutral
Apr-22-16UpgradeJP MorganNeutral → Overweight
Jun-04-13DowngradePiperJaffrayOverweight → Neutral
Latest News
Jun-16-26
Jun-16-2604:04PM
Rigel Pharmaceuticals Closes Its Licensing Agreement for VEPPANU; The Agreement Is Effective As Of June 11, 2026 And Rigel Has Made The Upfront Payment Of $70.0M To Be Distributed Evenly Between Arvinas And Pfizer, Consistent With The Terms Of The AgreementBenzinga
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue300294179
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A212019
Gross Profit280275161
Selling, General and Administrative Excl. Other119116113
Research and Development373323
Other Operating Expense-100
Operating Income12412524
Interest Expense778
Unusual Expense
———
Non-Operating Income (Expense)-4-4-2
Net Income Before Taxes12312218
Income Taxes-242-2451
Consolidated Net Income36536717
Net Income From Continuing Operations36536717
Net Income36536717
EPS (Recurring)20.0720.400.99
EPS (Basic, Before Extraordinaries)20.0720.400.99
EPS (Diluted)18.7219.480.99
EBITDA13113229
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio1.762.20—
Price To Sales Ratio1.972.62—
Gross Margin93.3393.5489.94
Operating Margin41.3342.5213.41
Net Margin121.67124.839.50
Shares Outstanding181818
Market Capitalization592771—
Operating Lease Expense
———
Insider Trading Volume
$35.50$31.58$27.65$23.72$19.80● Close Price0.00K36.36K72.72K109.08K145.44KUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Schorno Dean LEVP & Chief Financial OfficerJun 01 '26Option Exercise14.836,762100,27879,718Jun 03 12:00 AM
Ali-Jackson KamilDirectorMay 26 '26Sale29.172,50072,92512,625May 28 12:00 AM
MOOS WALTER HDirectorFeb 20 '26Option Exercise24.008,000192,00016,722Feb 24 12:00 AM
MOOS WALTER HDirectorFeb 20 '26Sale36.364,000145,44012,722Feb 24 12:00 AM
RODRIGUEZ RAUL RCEO, PresidentJan 26 '26Option Exercise27.40120,0003,288,000285,243Feb 04 12:00 AM
Schorno Dean LEVP & Chief Financial OfficerDec 22 '25Option Exercise21.5113,000279,57264,235Dec 29 12:00 AM
Santos David AEVP, Chief Commercial OfficerFeb 05 '25Sale21.931,79639,37951,704Feb 06 12:00 AM
Schorno Dean LEVP & Chief Financial OfficerFeb 05 '25Sale21.931,73438,02057,235Feb 06 12:00 AM
RODRIGUEZ RAUL RCEO, PresidentFeb 05 '25Sale21.934,40096,474239,454Feb 06 12:00 AM
Furey Raymond J.EVP, GC, CCO & Corp SecFeb 05 '25Sale21.931,33929,35938,830Feb 06 12:00 AM
RODRIGUEZ RAUL RCEO, PresidentFeb 04 '25Sale20.924,952103,601243,854Feb 06 12:00 AM
Furey Raymond J.EVP, GC, CCO & Corp SecFeb 04 '25Sale20.921,44830,29440,169Feb 06 12:00 AM
Santos David AEVP, Chief Commercial OfficerFeb 04 '25Sale20.922,12544,45753,500Feb 06 12:00 AM
Schorno Dean LEVP & Chief Financial OfficerFeb 04 '25Sale20.922,03642,59558,969Feb 06 12:00 AM
RODRIGUEZ RAUL RCEO, PresidentJan 24 '25Option Exercise21.40135,0002,889,000250,584Jan 28 12:00 AM
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR